Citigroup Inc. (C) At $74.41 Forms Top; Novabay Pharmaceuticals (NYSEAMERICAN:NBY) Shorts Lowered By 5.84%

Novabay Pharmaceuticals Incorporated (NYSEAMERICAN:NBY) had a decrease of 5.84% in short interest. NBY’s SI was 64,500 shares in December as released by FINRA. Its down 5.84% from 68,500 shares previously. With 4,700 avg volume, 14 days are for Novabay Pharmaceuticals Incorporated (NYSEAMERICAN:NBY)’s short sellers to cover NBY’s short positions. The SI to Novabay Pharmaceuticals Incorporated’s float is 1.28%. The stock increased 5.45% or $0.19 during the last trading session, reaching $3.77. About 15,067 shares traded or 35.28% up from the average. NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) has risen 7.90% since December 31, 2016 and is uptrending. It has underperformed by 8.80% the S&P500.

Citigroup Inc. (C) formed multiple top with $79.62 target or 7.00% above today’s $74.41 share price. Citigroup Inc. (C) has $196.74B valuation. The stock decreased 0.89% or $0.67 during the last trading session, reaching $74.41. About 10.07M shares traded. Citigroup Inc. (NYSE:C) has risen 35.60% since December 31, 2016 and is uptrending. It has outperformed by 18.90% the S&P500.

NovaBay Pharmaceuticals, Inc., a pharmaceutical company, develops, makes, and markets anti-infective products for the eye care market in the United States. The company has market cap of $58.00 million. The Company’s commercial products include the Neutrox family of products, Avenova for the eye care market; Aganocide compounds patented synthetic molecules with a range of spectrum of uses against bacteria, viruses, and fungi; Auriclosene Irrigation Solution for urology; CelleRx for the dermatology market; intelli-Case, a device for soft and rigid gas permeable contact lenses; and NeutroPhase for wound care. It currently has negative earnings. The firm has collaboration and license agreement with Virbac to develop its Auriclosene compounds for veterinary markets.

Among 37 analysts covering Citigroup Inc. (NYSE:C), 19 have Buy rating, 3 Sell and 15 Hold. Therefore 51% are positive. Citigroup Inc. has $215 highest and $4.0 lowest target. $70.94’s average target is -4.66% below currents $74.41 stock price. Citigroup Inc. had 106 analyst reports since July 21, 2015 according to SRatingsIntel. The rating was maintained by Deutsche Bank on Wednesday, August 12 with “Hold”. The rating was initiated by Susquehanna with “Neutral” on Tuesday, October 6. As per Thursday, April 7, the company rating was maintained by JP Morgan. The rating was maintained by RBC Capital Markets on Monday, September 25 with “Buy”. Barclays Capital maintained the shares of C in report on Tuesday, January 3 with “Overweight” rating. On Monday, October 9 the stock rating was maintained by Citigroup with “Buy”. On Tuesday, January 10 the stock rating was downgraded by Standpoint Research to “Hold”. RBC Capital Markets maintained Citigroup Inc. (NYSE:C) rating on Thursday, June 22. RBC Capital Markets has “Buy” rating and $6500 target. As per Thursday, January 7, the company rating was upgraded by Portales Partners. RBC Capital Markets maintained it with “Buy” rating and $75.0 target in Friday, August 18 report.

Since August 4, 2017, it had 0 insider buys, and 2 sales for $3.05 million activity. 5,000 shares valued at $344,870 were sold by WALSH JEFFREY R on Friday, August 4. Shares for $2.70M were sold by Aristeguieta Francisco.

Investors sentiment increased to 1.35 in 2017 Q3. Its up 0.25, from 1.1 in 2017Q2. It increased, as 56 investors sold Citigroup Inc. shares while 400 reduced holdings. 125 funds opened positions while 492 raised stakes. 2.04 billion shares or 0.42% more from 2.03 billion shares in 2017Q2 were reported. Utd Ser Automobile Association has invested 0.38% of its portfolio in Citigroup Inc. (NYSE:C). Savings Bank Of Ny Mellon invested in 0.92% or 46.11 million shares. Dnb Asset Mgmt As stated it has 2.15% of its portfolio in Citigroup Inc. (NYSE:C). Neville Rodie & Shaw Inc holds 0.06% or 7,015 shares in its portfolio. Cls Ltd Liability holds 0% or 266 shares. The Bermuda-based Fil Ltd has invested 2.67% in Citigroup Inc. (NYSE:C). Griffin Asset Management Inc reported 3,050 shares. James Invest Rech owns 24,381 shares. Eubel Brady And Suttman Asset, a Ohio-based fund reported 162,642 shares. Boothbay Fund Mngmt Ltd Com has 0.07% invested in Citigroup Inc. (NYSE:C) for 6,082 shares. Mufg Americas reported 209,796 shares or 0.49% of all its holdings. Saratoga And Invest accumulated 2,541 shares or 0.11% of the stock. Norinchukin Bancorporation The stated it has 0.21% in Citigroup Inc. (NYSE:C). Leuthold Group Limited Liability owns 54,885 shares. Commonwealth National Bank & Trust Of holds 0.37% or 522,431 shares.

Analysts await Citigroup Inc. (NYSE:C) to report earnings on January, 16 before the open. They expect $1.26 earnings per share, up 10.53% or $0.12 from last year’s $1.14 per share. C’s profit will be $3.33B for 14.76 P/E if the $1.26 EPS becomes a reality. After $1.42 actual earnings per share reported by Citigroup Inc. for the previous quarter, Wall Street now forecasts -11.27% negative EPS growth.